Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI remains negative
Q1 FY2026 Accumulated OCI was $6K, compared with $0 a year earlier.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- (1K) USD
- Year-over-year change
- —
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1K) | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Accumulated OCI vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Accumulated OCI amounts to 0.0% of total assets for UNCY, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$3.16M CAD | +20.3% | — | 13.6% |
| Mar 2026 | $3.06M USD | -22.1% | -4.4% | 1.6% | |
CBUSCibus, Inc. | Mar 2026 | $25K USD | -7.4% | — | 0.0% |
| Mar 2026 | $6K USD | — | — | 0.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $4K USD | -98.6% | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | -$7K USD | +0.0% | — | 0.0% | |
| Mar 2026 | -$15K USD | -117.9% | — | 0.0% | |
| Peer median (excluding UNCY) | — | -14.8% | -4.4% | 0.0% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.